Angelika Witoslawska, Jennifer M T A Meessen, Mika Hilvo, Antti Jylhä, Faiez Zannad, Marianna Cerrato, Patrick Rossignol, Deborah Novelli, Kevin Duarte, Giovanni Targher, Roberto Latini, Nicolas Girerd, Reijo Laaksonen
{"title":"Ceramide and phosphatidylcholine lipids-based risk score predicts major cardiovascular outcomes in patients with heart failure.","authors":"Angelika Witoslawska, Jennifer M T A Meessen, Mika Hilvo, Antti Jylhä, Faiez Zannad, Marianna Cerrato, Patrick Rossignol, Deborah Novelli, Kevin Duarte, Giovanni Targher, Roberto Latini, Nicolas Girerd, Reijo Laaksonen","doi":"10.1111/eci.14359","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ceramide and phosphatidylcholine lipids-based risk score (CERT2) has shown a strong prognostic value in predicting cardiovascular (CV) events in patients with ischemic heart disease. This study aimed to investigate the prognostic value of CERT2 risk score in patients with heart failure (HF).</p><p><strong>Methods: </strong>The current study combines data for 4234 subjects from the COMMANDER-HF trial and 1227 subjects from the GISSI-HF trial, which enrolled patients with a history of HF. The CERT2 risk score was calculated for all the participants as previously described. The primary outcome was CV death, but all-cause death and major adverse CV events (three-point MACE) were analysed as well.</p><p><strong>Results: </strong>After adjustment for established CV risk factors and potential confounders, patients with the highest CERT2 risk category remained at almost three-fold higher risk of CV death (COMMANDER-HF: HR 2.80, 95% CI 2.18-3.60, GISSI-HF: 2.84, 95% CI 1.70-4.74), all-cause death (COMMANDER-HF: HR 2.97, 95% CI 2.36-3.75, GISSI-HF: 2.83, 95% CI 1.83-4.38) and MACE (COMMANDER-HF: HR 2.73, 95% CI 2.20-3.38, GISSI-HF: 2.67, 95% CI 1.67-4.26) compared to those with the lowest CERT2 risk category.</p><p><strong>Conclusions: </strong>The CERT2 risk score is strongly associated with an increased risk of CV death, all-cause death and MACE in patients with HF.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e14359"},"PeriodicalIF":4.4000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.14359","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Ceramide and phosphatidylcholine lipids-based risk score (CERT2) has shown a strong prognostic value in predicting cardiovascular (CV) events in patients with ischemic heart disease. This study aimed to investigate the prognostic value of CERT2 risk score in patients with heart failure (HF).
Methods: The current study combines data for 4234 subjects from the COMMANDER-HF trial and 1227 subjects from the GISSI-HF trial, which enrolled patients with a history of HF. The CERT2 risk score was calculated for all the participants as previously described. The primary outcome was CV death, but all-cause death and major adverse CV events (three-point MACE) were analysed as well.
Results: After adjustment for established CV risk factors and potential confounders, patients with the highest CERT2 risk category remained at almost three-fold higher risk of CV death (COMMANDER-HF: HR 2.80, 95% CI 2.18-3.60, GISSI-HF: 2.84, 95% CI 1.70-4.74), all-cause death (COMMANDER-HF: HR 2.97, 95% CI 2.36-3.75, GISSI-HF: 2.83, 95% CI 1.83-4.38) and MACE (COMMANDER-HF: HR 2.73, 95% CI 2.20-3.38, GISSI-HF: 2.67, 95% CI 1.67-4.26) compared to those with the lowest CERT2 risk category.
Conclusions: The CERT2 risk score is strongly associated with an increased risk of CV death, all-cause death and MACE in patients with HF.
背景：基于神经酰胺和磷脂酰胆碱脂质的风险评分（CERT2）在预测缺血性心脏病患者的心血管（CV）事件方面具有很高的预后价值。本研究旨在探讨 CERT2 风险评分在心力衰竭（HF）患者中的预后价值：本研究合并了 COMMANDER-HF 试验中 4234 名受试者的数据和 GISSI-HF 试验中 1227 名受试者的数据。所有受试者的 CERT2 风险评分均按前述方法计算。主要结果是冠心病死亡，但也分析了全因死亡和主要不良冠心病事件（三分 MACE）：结果：在对已确定的心血管疾病风险因素和潜在混杂因素进行调整后，CERT2 风险类别最高的患者发生心血管疾病死亡的风险仍然高出近三倍（COMMANDER-HF：HR 2.80，95% CI 2.18-3.60；GISSI-HF：2.84，95% CI 1.70-4.74）。74）、全因死亡（COMMANDER-HF：HR 2.97，95% CI 2.36-3.75；GISSI-HF：2.83，95% CI 1.83-4.38）和MACE（COMMANDER-HF：HR 2.73，95% CI 2.20-3.38；GISSI-HF：2.67，95% CI 1.67-4.26）：CERT2风险评分与心房颤动患者心血管死亡、全因死亡和MACE风险的增加密切相关。
期刊介绍：
EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
